2902 Flurazepam Flurazepam belongs to the 1,4-benzodiazepines, a subclass of benzodiazepines within the organic compounds. This exogenous organoheterocyclic compound has the formula C21H23ClFN3O and an average molecular weight of 387.88 g/mol. At room temperature, it exists as a solid. It is used as a hypnotic and sedative, with oral exposure recorded. The compound is found in or released from 13 recorded sources. These include drinking water and water supply; food preservation within food, food processing, and cookware; household cleaning and consumer products such as perfumes within detergents and soaps, tobacco smoke filters, cigar cigarettes, non-electric simulated smoking devices, and other smoking requisites; and electrical and electronic equipment, including antennas, conductors or conductive bodies characterised by the conductive materials, electrodes, radio transmission systems, and electrically stimulated smoking devices. Flurazepam has 20 recorded protein targets, including gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1), alpha-5 (GABRA5), beta-1 (GABRB1), beta-3 (GABRB3), gamma-1 (GABRG1), gamma-2 (GABRG2), gamma-3 (GABRG3), and delta (GABRD), among 7 other proteins. Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane. 17617-23-1 3393 C21H23ClFN3O 387.151370 White powder. 190-220°C 500 mg/mL (HCl salt) Oral. Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form Route of Elimination: Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam. Half Life: The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours No indication of carcinogenicity to humans (not listed by IARC). For short-term and intermittent use in patients with recurring insomnia and poor sleeping habits They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. Coma, confusion, low blood pressure, sleepiness General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension and CNS depression may be combated by judicious use of appropriate therapeutic agents. If excitation occurs in patients following Flurazepam overdosage, barbiturates should not be used. Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be useful in situations when an overdose with a benzodiazepine is known or suspected. (L1712) 2009-07-21T20:27:25Z 2026-05-14T16:46:10Z Flurazepam 195929 Flurazepam DB00690 true CCN(CC)CCN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C1=CC=CC=C1F C21H23ClFN3O InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3 SAADBVWGJQAEFS-UHFFFAOYSA-N 387.878 387.151368285 Exogenous Solid 3.8 HMDB14828 CHEMBL968 3276 <p>Fryer, R. and Sternbach, L.H.; U.S. Patent 3,567,710; March 2, 1971; assigned to Hoffman-La Roche, Inc.</p> CHEM002248 DTXSID1023071 NS00010460 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one 35.910000000000004 107.54460000000003 41.220640768421966 6 3 0 8.71035223145298 1 3 3.81 -4.59 1.00e-02 g/l Organic compounds Organoheterocyclic compounds Benzodiazepines 1,4-benzodiazepines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 776t3gAAAAAQAAAAAwAAAAAAAAAbAAAAHQAAAIABBgBgAAAAAQMGAGAAAAAC AgcAIAAAAAMGAGAAAAACAgYAYAAAAAEDBgBgAAAAAgIGAGAAAAACAgcAKAAA AAMDBkAoAAAAAwQGQCgAAAADBAZAaAAAAAMDAQZAKAAAAAMEEQAgAAAAAQZA aAAAAAMDAQZAaAAAAAMDAQYAKAAAAAMEBwAoAAAAAwMGAGAAAAACAgYAKAAA AAMECAAoAAAAAwIGQCgAAAADBAZAaAAAAAMDAQZAaAAAAAMDAQZAaAAAAAMD AQZAaAAAAAMDAQZAKAAAAAMECQAgAAAAAQsAAQABAgACAwADBAACBQAFBgAG BwAHCCAICWgMCQpoDAoLaAwLDAALDWgMDQ5oDAkPIA8QKAIQEQAREgASEygC DxQgFBVoDBUWaAwWF2gMFxhoDBgZaAwZGgASByAZFGgMDghoDEIDAAAABwcI CQ8QERIGCgsNDggJBhUWFxgZFBcEAAAAAAAAABY= 2026-09-19T04:00:37Z